Ioanna Kouremenou

Intelligencia

Intelligencia uses Artificial Intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We therefore aim to bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers brings together and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning fueled predictions to enable critical decision making. We currently work with several of the largest global pharmaceutical companies, as well as with mid-size and smaller biotechnology companies. Diseases will impact nearly every individual. At Intelligencia, we work to make a difference.